Form 4: Fulgent Genetics Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports disposition of shares to cover tax obligations.
Summary
- On March 1, 2025, Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc., disposed of 985 shares of common stock to cover tax withholding obligations.
- The transaction was executed at a price of $15.45 per share.
- Following the transaction, Gao Hanlin beneficially owns 964,310 shares of Fulgent Genetics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock transactions, and the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies. It provides transparency into the trading activities of company officers.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small number of shares being sold to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of restricted stock units granted to the reporting person |
| March 2, 2022 | Date Form 4 was filed with the U.S. Securities and Exchange Commission regarding the restricted stock units |
| 03/01/2025 | Date of stock transaction |
| 03/04/2025 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.